Biogen Idec’s board of directors has authorized management to evaluate the potential sale of the company. BI’s business outlook, released on September 6, expressed the company’s quest to generate strong operating and financial performance by the end of 2010. The company’s strategy included the following goals: getting 100,000 patients on MS treatment Tysabri; having more than 40% of revenue coming from its International business; launching four new products and/or ex...